The estimated Net Worth of Steven S Myers is at least $63.1 Thousand dollars as of 8 December 2021. Mr. Myers owns over 33,785 units of Caladrius Biosciences Inc stock worth over $63,141 and over the last 9 years he sold CLBS stock worth over $0. In addition, he makes $0 as Independent Director at Caladrius Biosciences Inc.
Steven has made over 1 trades of the Caladrius Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 33,785 units of CLBS stock worth $30,069 on 8 December 2021.
The largest trade he's ever made was buying 33,785 units of Caladrius Biosciences Inc stock on 8 December 2021 worth over $30,069. On average, Steven trades about 2,815 units every 0 days since 2015. As of 8 December 2021 he still owns at least 146,839 units of Caladrius Biosciences Inc stock.
You can see the complete history of Mr. Myers stock trades at the bottom of the page.
Steven S. Myers serves as Independent Director of the Company. He graduated from Stanford University with a B.S. in Mathematics. He is a four-time serial entrepreneur, an Ernst & Young “Entrepreneur of the Year” for Software and Information Services, and a recipient of the California Governor’s Special Recognition Award. Mr. Myers has served as a Director on the LSI Business Development, Inc. board since January 2019. He previously served on the boards of Spikes Security, Inc., QuantumSphere, Inc., the Pacific Council of International Policy and the Bel Air Association. He has conducted business in a dozen countries in Europe and Asia. He also serves as a Director of his private equity investment company, Dolphin Capital Holdings, Inc., which invests in companies with innovative business strategies. Portfolio investments include regenerative medicine, biotechnology, medical devices, applied materials development, alternative energy, distressed debt, and for income real estate. An Administration policy advisor on Cyber Security, he served in 2012 on the Department of Homeland Security Task Force on Cyber Security Resources and briefed then-DHS Secretary Napolitano on the Task Force recommendations. He was recently appointed to a third term on the U.S. State Department Advisory Committee on International Economic Policy, which advises the Secretary of State on foreign policy issues. At the Pacific Council on International Policy he serves on the Board of Directors and is Chairman of their National Security Member Committee.
Steven Myers is 73, he's been the Independent Director of Caladrius Biosciences Inc since 2006. There are no older and 15 younger executives at Caladrius Biosciences Inc.
Steven's mailing address filed with the SEC is C/O CALADRIUS BIOSCIENCES, INC., 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE, NJ, 07920.
Over the last 9 years, insiders at Caladrius Biosciences Inc have traded over $244,786 worth of Caladrius Biosciences Inc stock and bought 202,695 units worth $275,173 . The most active insiders traders include Richard J Berman, Steven M Klosk, and Peter G Traber. On average, Caladrius Biosciences Inc executives and independent directors trade stock every 178 days with the average trade being worth of $17,064. The most recent stock trade was executed by Steven S Myers on 8 December 2021, trading 33,785 units of CLBS stock currently worth $30,069.
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).
Caladrius Biosciences Inc executives and other stock owners filed with the SEC include: